• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Anti-Nausea Based Drug Reduces Alzheimer`s Astrocytes In Mice

    FIERCE BIOTECH

    Nanoform, PlusVitech Partner To Repurpose Aprepitant For Lung Cancer

    PR NEWSWIRE

    FDA Confirms Paragraph IV Patent Litigation for Aprepitant Intravenous Emulsion

    FDA

    Heron scores FDA for Aponvie, alternative to pills for postoperative nausea

    FIERCEPHARMA

    FDA Confirms Paragraph IV Patent Litigation for Aprepitant, Azilsartan, Bupivacaine, Cladribine, Elrombopag, Fosnetupitant, Fostamatinib, Ivacaftor and Sodium Thiosulfate.

    FDA

    FDA Confirms Paragraph IV Patent Litigation for Aprepitant

    FDA

    Heron Submits HTX-019 NDA for Prevention of Postoperative Nausea and Vomiting

    PRNEWSWIRE

    Torrent Pharms Generic Aprepitant Receives Approval in US

    FDA

    Heron Therapeutics Announces Initiation of Phase 2 Clinical Study of CINVANTI®

    PRNEWSWIRE

    Heron Announces FDA Approval of sNDA to Expand CINVANTI® Label for IV Push

    PR NEWSWIRE

    Enforcement Report - Week of December 26, 2018

    FDA

    Glenmark Pharm’s Generic Aprepitant Receives Approval In US

    FDA

    Facing off rivals, Merck looks to expand CINV label on positive PhIII Emend study

    FIERCE BIOTECH

    Attix Pharmaceuticals Recalls Hundreds of APIs From the U.S.

    FIERCE PHARMA MFG

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.